MPI and Oncology Venture enters three new agreements on DRP's

2016-04-27

Hoersholm; April 27th, 2016 - Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that MPI has sold three DRP's to Oncology Venture for three new selected compounds combined with MPI's DRP(TM) for anti-cancer treatment.

Oncology Venture is pioneering a novel way of improving clinical outcomes in the field of oncology. Many drugs have achieved encouraging levels of complete and partial responses but not enough to warrant approval. The drugs will be developed with MPI's DRP(TM) to enrich the patient population with the goal of increasing the response rate. The DRP(TM) can be used for all cancer diseases and for most anti-cancer drugs on the market or under development.

"We are excited at that Oncology Venture have identified compounds they find promising to develop together with the DRP(TM) and will aim to progress into approvable anti-cancer drugs," says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO at MPI. "This is precisely where MPI's DRP(TM) makes a difference." adds Peter Buhl Jensen.

About MPI's multiple biomarker called Drug Response Predictor - DRP(TM)
MPI's DRP(TM) is a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The DRP(TM) has been tested in 37 trials, where 29 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients responded well to the treatment. The DRP(TM) platform has amongst others been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given   anti-cancer drug.  In addition to this, the individual genetic patterns of patients can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of patients with a high likelihood of response to the drug. DRP(TM) builds on comparison between sensitive and resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. MicroRNA is used on certain products whereas the messengerRNA is more broadly useable and more validated. The DRP(TM) platform can be used in all cancer types, and has been patented for more than 60 anti-cancer drugs in the US.

About MPI
Medical Prognosis is a publicly traded international company specialized in improving cancer patients lives by developing Personalized Medicine using its unique DRP(TM) technology. MPI's exceptional opportunity to personalize cancer treatment - begins with Breast Cancer moving on to Multiple Myeloma and Prostate Cancer as the first steps. MPI's DRP(TM) tool has shown its ability to separate patients who benefit and who do not benefit from a specific cancer treatment. This has been shown in as many as 29 out of 37 trials, and covers more than 80 anti-cancer treatments in a wide range of cancer indications. MPI has built a significant large database with over 1,000 screened breast cancer patients and is building up a database in Multiple Myeloma to be followed by Prostate cancer in collaboration with oncologists and hematologists throughout Denmark.

For further information, please contact

Peter Buhl Jensen, CEO
e-mail: pbj@medical-prognosis.com
Phone: +45 21 60 89 22

Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark